Standout Papers
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial (2014)
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia (2012)
Immediate Impact
6 by Nobel laureates 6 from Science/Nature 85 standout
Citing Papers
Past, present, and future of CRISPR genome editing technologies
2024 Standout
Mechanisms of long COVID and the path toward therapeutics
2024 Standout
Works of Ian Bridges being referenced
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels
2015
Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
2012 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ian Bridges | 1263 | 546 | 194 | 310 | 31 | 1.5k | |
| Jason C. Legg | 1364 | 602 | 251 | 368 | 36 | 2.0k | |
| Ricardo Dent | 1583 | 672 | 205 | 334 | 40 | 1.9k | |
| Mahfouz El Shahawy | 1431 | 590 | 252 | 393 | 11 | 1.8k | |
| Maria Laura Monsalvo | 1297 | 588 | 231 | 344 | 31 | 1.5k | |
| Patrick M. Moriarty | 1240 | 327 | 184 | 336 | 39 | 1.6k | |
| David Neff | 915 | 293 | 87 | 383 | 39 | 1.3k | |
| Feng Xu | 964 | 267 | 149 | 191 | 43 | 1.5k | |
| Anja Vogt | 1063 | 289 | 148 | 336 | 62 | 1.4k | |
| Garen Manvelian | 1172 | 340 | 206 | 167 | 54 | 1.6k | |
| Estella Kanevsky | 1725 | 461 | 278 | 541 | 14 | 2.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...